The Regeneron, Alphabet and GlaxoSmithKline-backed hearing loss therapy developer has filed to raise up to $75m in its initial public offering.
US-based hearing loss drug developer Decibel Therapeutics has filed for a $75m initial public offering that would give pharmaceutical companies Regeneron and GlaxoSmithKline (GSK) and internet technology group Alphabet the chance to exit.
Decibel is working on gene therapies intended to treat hearing loss and restore hearing balance by restoring functional hair cells and non-sensory support cells in the inner ear.
A product candidate called DB-020 is in a phase 1b clinical trial for the prevention of hearing loss…
